[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100581449":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":53,"collaborators":25,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":25,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":25,"enrollmentInfo":66,"targetDuration":25,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":39,"whyStopped":25,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Mahidol University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"olanzapine","EXPERIMENTAL","olanzapine 5 mg on day 1-4",[13],"Drug: olanzapine",{"label":15,"type":16,"description":17,"interventionNames":18},"placebo","PLACEBO_COMPARATOR","placebo 5 mg day 1-4",[19],"Drug: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","olanzapine 5 mg oral prior to chemotherapy on day 1 and daily on day 2-4",[9],null,{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Placebo","placebo 5 mg oral prior to chemotherapy on day 1 and daily on day 2-4",[15],[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Suthinee Ithimakin Ithimakin, MD","CONTACT","66898127440","aesi105@yahoo.co.th",[37],{"facility":38,"status":39,"city":40,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Faculty of Medicine Siriraj Hospital, Mahidol University","RECRUITING","Bangkok","10700","Thailand","TH",{"type":45,"coordinates":46},"Point",[47,48],100.50144,13.75398,{"lat":48,"lon":47},[51],{"name":52,"role":33,"phone":34,"phoneExt":25,"email":35},"Suthinee Ithimakin, MD",{"type":54,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","suthinee ithimakin","Associate professor","100581449","phase-3-olanzapine-versus-placebo-for-moderately-emetogenic-chemotherapy-100581449",false,"NCT06850454","Olanzapine Versus Placebo for Moderately Emetogenic Chemotherapy","A Prospective Randomized, Double-blind Controlled Trial of Olanzapine Versus Placebo in Addition to Ondansetron Plus Dexamethasone As Antiemetic Prophylaxis in Patients Receiving Moderately Emetogenic Chemotherapy","Inclusion Criteria:\n\n* histologically confirmed cancer patients who will be started on first dose of oxaliplatin, irinotecan or carboplatin\n* age of \\>18 years old\n\nExclusion Criteria:\n\n* pregnancy or breast feeding\n* has emetic episode within 24 hours\n* gut obstruction\n* uncontrolled brain metastasis\n* allergy to or current use of olanzapine\n* concomittant moderate or high emetogenic chemotherapy on day 2-5\n* Total bilirubin \\> 2 mg\u002Fdl or creatinine clearance \\\u003C 30 ml\u002Fmin\n* unable to swallow drug","ALL","18 Years",{"count":67,"type":68},140,"ESTIMATED","INTERVENTIONAL",[71],"PHASE3","A study comparing efficacy of olanzapine versus placebo to prevent nausea and vomiting from moderate emetic risk chemotherapy",[74],"Chemotherapy Induced Nausea and Vomiting",[9,76,77,78,79],"moderately emetogenic chemotherapy","carboplatin","irinotecan","oxaliplatin","2025-02-21",{"date":82,"type":83},"2025-02-27","ACTUAL",{"date":85,"type":83},"2025-01-10",{"date":87,"type":68},"2026-01-31",{"name":5,"class":6},1]